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To evaluate trends in allografting from unrelated donors, we conducted a study on 196 consecutive myeloma
patients transplanted between 2000 and 2009 in Italy. Twenty-eight percent, 37%, and 35%, respectively,
received myeloablative, reduced-intensity, and nonmyeloablative conditioning. In these 3 cohorts, 1-year and
5-year transplantation-related mortalities were 28.8% and 37.0%, 20.3% and 31.3%, and 25.0% and 30.3%,
respectively (P ¼ .745). Median overall survival (OS) and event-free survival from transplantation for the 3
cohorts were 29 and 10 months, 11 and 6 months, and 32 and 13 months, respectively (P ¼ .039 and
P ¼ .049). Overall cumulative incidences of acute and chronic graft-versus-host-disease (GVHD) were 46.1%
and 51.1%. By Cox multivariate analyses, chronic GVHD was signiﬁcantly associated with longer OS (hazard
ratio [HR], .51; P ¼ .009), whereas the use of peripheral blood stem cells was borderline signiﬁcant (HR, .55;
P ¼ .051). Better response posttransplantation was associated with longer event-free survival (HR, 2.13 to
4.25; P < .001). Acute GVHD was associated with poorer OS (HR, 2.53; P ¼ .001). This analysis showed
a strong association of acute and chronic GVHD and depth of response posttransplantation with clinical
outcomes. Long-term disease control remains challenging regardless of the conditioning. In the light of these
results, prospective trials may be designed to better deﬁne the role of allografting from unrelated donors in
myeloma.
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13.03.012decade. Several changes in transplantation procedures and
better supportive care have also contributed to signiﬁcantly
improve clinical outcomes [1]. Recent activity surveys by the
European Group for Blood and Marrow Transplantation
(EBMT) have shown that the number of allografts performed
from unrelated donors is currently higher that those from
HLA-identical siblings in Europe [2,3]. As for plasma cell
disorders, 569 allografts were performed in 2009 with
a remarkable increase as compared with 2004 [2]. InTransplantation.
Table 1
Characteristics of Patients Who Underwent an Allograft from an Unrelated
Donor
Characteristic Number
Study period 2000-2009
Patients 196
Allografts 199
Median age, yr (range) 51 (32-67)
Male 120 (60%)
Myeloma stage at diagnosis (Durie & Salmon)*
Stage I-II 42 (21%)
Stage III 140 (70%)
Myeloma isotype
IgG 115 (58%)
IgA 34 (17%)
IgM 1 (<1%)
Bence Jones 33 (16%)
Nonsecretory 3 (1%)
Conditioning*
Myeloablative 52 (28%)
Nonmyeloablative 64 (35%)
Reduced intensity 69 (37%)
Therapy lines before transplant*
2 86 (43%)
>2 99 (50%)
Recipientedonor HLA matched alleles
10/10 102 (52%)
9/10 62 (31%)
8/10 34 (17%)
Median time from diagnosis to transplant, mo 33 (range 5-171)
* Data not reported in 14 transplants.
Figure 1. Number of allografts by year and trends in conditioning regimens
over the study period.
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myeloma in 2010 and over 50% were from unrelated donors
[3]. Unfortunately, only aminority of patient were enrolled in
prospective clinical trials.
To observe trends and to report clinical outcomes in
allografting from unrelated donors for the treatment of
multiple myeloma in Italy, we conducted a retrospective
study through the Italian Bone Marrow Donor Registry
(IBMDR) over a 10-year period from 2000 to 2009 (http://
ClinicalTrials.gov; NCT01440556).METHODS
Patients
From 2000 through 2009, 196 patients, median age 51 years (range, 32
to 67 years), underwent transplanted from an unrelated donor in Italy.
Clinical data were retrieved from the central data management system
Project Manager Internet Server (ProMISe) used by the EBMT and from the
IBMDR where patients are followed longitudinally with at least yearly
follow-up. Furthermore, patient forms for speciﬁc queries were sent to each
participating center to complete data collection. The study was approved by
the Italian Committee for Unrelated Donor Marrow Transplantation and by
the institutional review board of the coordinating center, San Giovanni
Battista Hospital, University of Torino, Torino, Italy, according to the Decla-
ration of Helsinki (http://ClinicalTrials.gov; NCT01440556).Statistical Analysis
Primary endpoints were overall survival (OS) from diagnosis and from
the allograft and event-free survival (EFS) from the allograft. OS was deﬁned
as the date from diagnosis and from the allograft to death from any cause,
whereas EFS was deﬁned as the date from the allograft to disease progres-
sion/relapse or death from any cause, whichever occurred ﬁrst. Alive
patients without progression/relapse were censored as of March 31, 2012.
Patient characteristics were comparedwith Fisher’s exact test for categorical
variables and with Mann-Whitney test for continuous variables. Survivals
were calculated by the Kaplan-Meier method and analyzed by the Cox
proportional hazards model, comparing the 2 arms by the Wald test and
calculating 95% conﬁdence intervals (CIs) [4,5].
Univariate and multivariate analyses were performed for the following
variables: Durie-Salmon stage, number of previous chemotherapy lines (>2
versus 2), exposure to “new drugs” (thalidomide, lenalidomide, bortezo-
mib) before the allograft, disease status at transplantation, HLA-matchedalleles (8/10 versus 9/10 versus 10/10), recipientedonor gender combi-
nations, stem cell source (bone marrow versus peripheral blood stem cells
[PBSCs]), conditioning (nonmyeloablative versus reduced intensity versus
myeloablative), acute graft-versus-host disease (GVHD), chronic GVHD, best
response posttransplantation, and year of transplantation (2006 to 2009
versus 2003 to 2005 versus 2000 to 2002). Conditionings were deﬁned as
myeloablative, reduced intensity or nonmyeloablative as previously
described [6].
Response criteria were deﬁned as complete remission (CR), partial
remission (PR), and stable and progressive disease (SD-PD) according to the
International Uniform Response Criteria for multiple myeloma [7]. Best
response posttransplantation and acute and chronic GVHD were treated as
time-dependent variables. Moreover, to fully evaluate the confounding role
of “disease status at transplantation” and “best response post-
transplantation” in multivariate analyses, the previous Cox multivariate
models were also estimated omitting these 2 variables. Cumulative inci-
dences of grades II to IV acute GVHD, overall, limited and extensive chronic
GVHD, and transplantation-related mortality (TRM) were estimated by the
Fine and Gray competing risk regression models as previously described [8].
TRM was deﬁned as death without previous relapse. Death without acute
GVHD was considered a competing risk for acute GVHD, whereas death
without chronic GVHD for overall chronic GVHD, limited and extensive
chronic GVHD, and relapse was considered a competing event for TRM.
All P values were 2-sided at the conventional 5% signiﬁcance level.
Follow-up was updated as of March 31, 2012. Data were analyzed as of
November 2012 by IBM SPSS 21.0. (Armonk, NY) and R 3.0.0 (R Foundation
for Statistical Computing, Vienna, Austria) package cmprsk.
RESULTS
Study Population
Over the 10-year study period (January 2000 to October
2009), 649 unrelated volunteer donor searches for myeloma
patients were started through the IBMDR. As of October 31,
2009,196 patients received transplantations after identifying
a suitable unrelated donor at 34 centers; 3 patients received
2 allografts for a total of 199 transplantations. Median time
from the start of the donor search to transplantation was
7 months. Patient characteristics are reported in Table 1.
Patients were also divided into 3 cohorts depending on
the year of transplantation: 26 in 2000 to 2002, 57 in 2003 to
2005, and 116 in 2006 to 2009. Patients were also divided by
conditioning regimen: 52 were assigned the myeloablative
conditioning regimen, 69 the reduced intensity, and 64 the
nonmyeloablative (conditioning regimenwas unknown in 14
transplantations) (Figure 1). Patient median age at trans-
plantation for the 3 cohorts was 45 years (range, 32 to
63 years), 53 years (range, 33 to 65 years), and 55 years
(range, 38 to 67 years), respectively (P < .001).
Table 2
Transplant Characteristics of 3 Patient Cohorts Deﬁned by Year of Transplant and Conditioning Regimen
Year of Transplant Stem Cell Source
No. of Transplants
Therapy Lines Before Transplant
No. of Patients
Use of ATG
No. of Transplants
Conditioning Regimen*
No. of Transplants
BM vs. PBSC 2 vs. >2 Yes vs. No M vs. R vs. NM
2000-2002 21 (84%) vs. 5 (19%) 14 (54%) vs. 12 (46%) 18 (70%) vs. 8 (30%) 16 (70%) vs. 6 (26%) vs. 1 (4%)
2003-2005 12 (21%) vs. 45 (79%) 23 (40%) vs. 34 (60%) 29 (51%) vs. 28 (49%) 17 (32%) vs. 14 (26%) vs. 22 (42%)
2006-2009 16 (14%) vs. 100 (86%) 61 (53%) vs. 55 (47%) 63 (55%) vs. 53 (45%) 19 (17%) vs. 49 (45%) vs. 41 (38%)
Conditioning Regimen* Stem Cell Source
No. of Transplants
Therapy Lines Before Transplant
No. of Patients
Use of ATG
No. of Transplants
Year of Transplant
No. of Transplants
BM vs. PBSC 2 vs. >2 Yes vs. No 2000-2002 vs. 2003-2005 vs. 2006-2009
Myeloablative 24 (46%) vs. 28 (54%) 23 (44%) vs. 29 (56%) 45 (86%) vs. 7 (14%) 16 (31%) vs. 17 (33%) vs. 19 (36%)
Reduced intensity 18 (26%) vs. 51 (74%) 33 (48%) vs. 36 (52%) 53 (77%) vs. 16 (23%) 6 (9%) vs. 14 (20%) vs. 49 (71%)
Nonmyeloablative 0 (0%) vs. 64 (100%) 30 (47%) vs. 34 (53%) 10 (16%) vs. 54 (84%) 1 (2%) vs. 22 (34%) vs. 41 (64%)
BM indicates bone marrow; M, myeloablative; R, reduced intensity; NM, nonmyeloablative vs., versus.
* Conditioning regimen was unknown in 14 transplants.
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Most patients were heavily pretreated and received
a median of 3 (range, 1 to 7) lines of therapy before the allo-
graft. One hundredﬁfty of 196 patients (76%) also received so-
callednewdrugs: 71of150 (47%) received thalidomideand/or
lenalidomide, 28 of 150 (19%) received only bortezomib, and
51 of 150 (33%) received both thalidomide/lenalidomide and
bortezomib. One hundred seventy-ﬁve of 196 patients (89%)
had received at least 1 autograft; 12 of 196 (6%) had not
undergone anautograft (dataweremissing in9patients [4%]).
Median time from diagnosis and from the autograft to the
unrelated donor allograftwas 16months (range, 2 to 150) and
33 months (range, 5 to 171), respectively.Conditioning Regimens, Stem Cell Source, and GVHD
Prophylaxis
Conditioning regimens
Myeloablative regimens consisted primarily of
cyclophosphamideetotal body irradiation (TBI) and
cyclophoshamideebusulfan. Some patients received high-
dose busulfan associated with melphalan, ﬂudarabine, or
thiotepaeﬂudarabine. Other regimens included
melphalanecyclophosphamideeTBI, melphalaneTBI, and
treosulphaneﬂudarabine. Nonmyeloablative regimens con-
sisted of low-dose TBI (200 cGy) with ﬂudarabine. Reduced-
intensity regimens consisted of melphalaneﬂudarabine
based or thiotepaecyclophosphamide based conditionings.
The use of myeloablative regimens remained steady during
the study period, whereas reduced-intensity and non-
myeloablative regimens remarkably increased over the years
(Figure 1, Table 2).
Stem cell source
PBSCs were the most frequently used stem cell source:
They were used in 150 of 199 transplants (75%), whereas
bone marrow was used in 49 of 199 transplants (25%). Bone
marrow was primarily associated with myeloablative regi-
mens in earlier years, whereas PBSCs were mostly used in
reduced-intensity and in all nonmyeloablative regimens in
recent years (Figure 1, Table 2).
GVHD prophylaxis
Myeloablative and reduced-intensity regimens were
associated with cyclosporineemethothrexate based GVHD
prophylaxis, whereas nonmyeloablative regimens were
associated with cyclosporineemycophenolate mophetil
prophylaxis. Moreover, antithymocyte globulin (ATG) wasused in 110 of 199 transplants (55%) as part of GVHD
prophylaxis (Table 2).
Transplant-Related Toxicity and Mortality
Overall cumulative incidence of acute grades II to IV
GVHD was 46.1%, whereas chronic GVHD was 51.1%
(Figure 2A, B). The cumulative incidences of acute and
chronic GVHD by type of conditioning were 41.2% and 42.9%,
50.0% and 40.1%, and 49.2% and 66.4% for myeloablative,
reduced-intensity, and nonmyeloablative regimens, respec-
tively. No statistically signiﬁcant difference in acute GVHD
cumulative incidence among the 3 cohorts was found
(P ¼ .803), whereas for chronic GVHD a borderline difference
was observed (P ¼ .052).
Overall cumulative incidence of TRM was 25.8% at 1 year
and 33.2% at 5 years posttransplantation, and the cumulative
incidence of its competing event (relapse) was 28.8% and
50.0%, respectively (Figure 2C). One-year and 5-year TRM
was 28.8% and 37.0%, 20.3% and 31.3%, and 25.0% and 30.3%
for myeloablative, reduced-intensity, and nonmyeloablative
regimens, respectively (P ¼ .745), whereas 1-year and 5-year
cumulative incidences of relapse were 21.2% and 46.0%, 42.1%
and 54.3%, and 20.3% and 45.7%, respectively (P ¼ .259).Disease Response
At the time of the allograft, 29 of 196 patients (14.8%)
were in CR and 87 of 196 (44.4%) in PR. Stratiﬁed by condi-
tioning, patients in CR, PR, and SD-PDwere 3 of 52 (6%), 23 of
52 (44%), and 26 of 52 (50%) for myeloablative; 9 of 69 (13%),
28 of 69 (41%), and 32 of 69 (46%) for reduced-intensity; and
15 of 64 (23%), 29 of 64 (45%), and 20 of 64 (31%) for non-
myeloablative regimens, respectively (P ¼ .052). After
a median follow-up from transplantation of 57 months
(range, 3 to 128), CR and PR in patients who survived at least
3months after transplant were 40% and 39%, respectively, for
an overall response rate of 79%.Clinical Outcomes
At a median follow-up of 93 months (range, 25 to 189)
from diagnosis, median OS from diagnosis of the entire study
populationwas 67months, whereas at a median follow-up of
57 months (range, 3 to 128) posttransplantation, median OS
and EFS from the allograft were 15 and 7 months, respec-
tively (Figure 3A). Overall, 57 of 196 patients died of disease
progression, whereas 71 of 196 died of transplant-related
causes.
Figure 2. (A) Cumulative incidence of acute grades II-IV GVHD. (B) Cumulative
incidence of chronic GVHD. (C) Cumulative incidence of TRM.
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76 months (range, 26 to 180), and 93 months (range, 25 to
183) from diagnosis, median OS was 71, 66, and 67 months
for myeloablative, reduced-intensity, and nonmyeloablative
regimens, respectively (P ¼ .362). At a median follow-up of
63 months (range, 3 to 128), 48 months (range, 10 to 103),and 58 months (range, 11 to 113) posttransplantation,
median OS and EFS from the allograft were 29 and
10 months, 11 and 6 months, and 32 and 13 months in
patients who underwent myeloablative, reduced-intensity,
and nonmyeloablative transplants, respectively (P ¼ .039
and P¼ .049; Figure 3B). OS (P¼ .646) and EFS (P¼ .456) from
the allograft in the 3 patient cohorts deﬁned by year of
transplantation are reported in Figure 3C.Factors Affecting OS and EFS
By univariate analyses, lower number of therapy lines
before the allograft, disease status at transplantation, a fully
matched (10/10 alleles) HLA-identical donor, the use of
PBSCs rather than bone marrow, and a better response
posttransplantation were statistically signiﬁcant variables
for OS, whereas disease status at transplant, limited chronic
GVHD, and a better response posttransplantation were
statistically signiﬁcant variables for EFS.
However, by multivariate analyses, only the use of PBSCs
(hazard ratio [HR], .55; P ¼ .051) and the development of
chronic GVHD (HR, .51; P ¼ .009) were signiﬁcant predictors
for longer OS, whereas acute GVHD (HR, 2.53; P ¼ .001) was
a signiﬁcant predictor for poorer OS. Most important
predictors for EFS were a better response
posttransplantation (PR versus CR: HR, 2.13; SD-PD versus
CR: HR, 4.25; P < .001) and the conditioning regimen
(reduced intensity versus myeloablative: HR, 1.96; P ¼ .001).
Complete univariate and multivariate analyses are reported
in Tables 3 and 4.
By omitting “disease status at transplantation” and “best
response posttransplantation” in the Cox multivariate
models, major predictors for shorter OS remained acute
GVHD (HR, 2.10; 95% CI, 1.29 to 3.41; P ¼ .003) and for longer
OS chronic GVHD (HR, .42; 95% CI, .26 to .69; P ¼ .001).
Conditioning regimen (reduced intensity versus myeloa-
blative: HR, 1.72; 95% CI, 1.04 to 2.84; P ¼ .035) and chronic
GVHD (HR, .48; 95% CI, .31 to .72; P < .001) were major
predictors for EFS.
DISCUSSION
The current role of allografting in multiple myeloma is
controversial [9,10]. The most recently published prospective
studies were designed before new drugs with potent anti-
myeloma activity became readily available [11,12], enrolled
newly diagnosed patients, used reduced-intensity or non-
myeloablative conditionings and donors were most
frequently HLA-identical siblings [13-23]. Conﬂicting results
were reported. Only a few published reports focused on
allografting from unrelated donors [24-28]. Our retrospec-
tive analysis through the IBMDR was intended to evaluate
trends in allografting from unrelated donors over the past
decade, with the ultimate goal of possibly offering recom-
mendations to our centers on timing and type of allograft
and on donor selection.
In our experience, the number of allografts gradually
increased over the study period. Overall, TRM at 1 year and
5 years was 25.8% and 33.2%, respectively. There was no
signiﬁcant difference in TRM (P ¼ .745) between condi-
tioning regimens. Incidence of acute GVHD was not signif-
icantly different among the 3 cohorts, whereas that of
chronic GVHD was borderline signiﬁcantly different
(P ¼ .052). Nonmyeloablative regimens showed a higher
cumulative incidence of chronic GVHD, presumably related
to the use of PBSCs. Patients conditioned with reduced-
Figure 3. (A) OS and EFS from the allograft of the entire study population. (B) OS and EFS of 3 patient cohorts deﬁned by conditioning regimen. (C) OS and EFS of 3
patient cohorts deﬁned by year of transplantation.
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older than those conditioned with a myeloablative regimen
(P < .001). This is not irrelevant given that the median age of
newly diagnosed myeloma patients is 67 to 68 years.Median OS and EFS of the entire study population were 15
and 7 months, respectively, and a subset have become
long-term disease-free survivors (Figure 3A). Even though
this study cannot offer a formal comparison among
Table 3
Univariate and Multivariate Analyses (Cox Models) for OS
Variable Univariate Analyses Multivariate
Analyses
HR 95% CI P HR 95% CI P
Durie-Salmon stage
(III vs. I-II)
1.27 .87-1.86 .218
Previous therapy lines
(>2 vs.  2)
1.54 1.09-2.17 .014 1.15 .71-1.88 .567
Disease status at transplant .009 .747
PR vs. CR 1.51 .84-2.71 .170 1.20 .49-2.93 .696
SD-PD vs. CR 2.25 1.26-4.01 .006 .98 .40-2.42 .965
Recipientedonor HLA
matched alleles
.010 .871
9/10 vs. 10/10 1.55 1.06-2.27 .025 1.14 .66-1.97 .642
8/10 vs. 10/10 1.91 1.20-3.03 .006 1.16 .54-2.50 .697
Recipientedonor gender
combinations
.866
f.f. vs. m.f. 1.26 .70-2.29 .441
m.m. vs. m.f. 1.20 .74-1.93 .459
f.m. vs. m.f. 1.16 .69-1.97 .571
New drugs before allograft
(yes vs. no)
.96 .65-1.41 .829
Source (PBSC vs.BM) .60 .41-.87 .007 .55 .30-1.00 .051
Conditioning .042 .163
R vs M 1.26 .82-1.93 .293 1.46 .81-2.66 .211
NM vs. M .72 .45-1.15 .173 .86 .43-1.69 .655
Acute GVHD* 1.49 .96-2.31 .078 2.53 1.50-4.28 .001
Chronic GVHD* .67 .34-1.34 .258 .51 .31-.84 .009
Chronic GVHD* .467
Limited vs. no GVHD .66 .34-1.28 .220
Extensive vs. no GVHD .80 .36-1.80 .597
Best response
posttransplantation*
.011 .349
PR vs. CR .97 .53-1.80 .926 .82 .41-1.64 .580
SD-PD vs. CR 2.35 1.09-5.06 .030 1.35 .54-3.37 .520
Year of transplant .647
2003-2005 vs. 2000-2002 .82 .48-1.39 .453
2006-2009 vs. 2000-2002 .79 .48-1.30 .789
f. indicates female; m., male; BM, bone marrow; R, reduced intensity;
M, myeloablative; NM, nonmyeloablative, vs., versus.
* Treated as a time-dependent variable.
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were observed among the 3 patient cohorts deﬁned by
conditioning (Figure 3B).
By multivariate analyses, acute and chronic GVHD were
variables signiﬁcantly associated with OS, whereas the
use of a myeloablative conditioning and best response
posttransplantation signiﬁcantly correlated with EFS
(Tables 3 and 4). The real impact of ATG on GVHD incidence
could not formally be assessed because ATG was almost
invariably associated with myeloablative and reduced-
intensity conditionings. The impact of antileukemia effects
associated with chronic GVHD was documented in many
reports [29-31].
With regard to the association between chronic GVHD
and graft-versus-myeloma effects, reports are somewhat
conﬂicting [17,19,32-34]. Ringdén et al. evaluated the impact
of acute and chronic GVHD on relapse and survival in
a cohort of 177 patients who received an allograft from HLA-
identical siblings after nonmyeloablative or reduced-
intensity conditionings [34]. Acute GVHD was signiﬁcantly
correlated with increased risk of TRM, whereas limited
chronic GVHD signiﬁcantly lowered the risk of myeloma
recurrence. However, in their retrospective experience, the
reduced relapse risk did not translate into better OS [34]. In
contrast, another study by Crawley et al. reported that
chronic GVHD was associated with better progression-free
survival and OS after reduced-intensity conditioning [33].In prospective studies, Björkstrand et al. did not report any
difference in OS and EFS between patients with and without
chronic GVHD after nonmyeloablative conditioning [20].
Similar ﬁndings were reported by others [17,19]. Differences
from study to study may be due to the design of the Cox
multivariate models: By omitting “disease status at trans-
plantation” and “best response post-transplant” in our
multivariate analyses, acute GVHD was a major predictor of
poorer OS (HR, 2.10; P ¼ .003) and chronic GVHD of signiﬁ-
cantly better OS (HR, .42; P ¼ .001) and EFS (HR, .48;
P < .001).
Even though best response posttransplantation was the
strongest predictor of better EFS but not of OS, this ﬁnding
stresses the importance of depth of response [35,36].
Consolidation and/or maintenance with new drugs may be
a widely applicable option to explore. The efﬁcacy of new
drugs such as thalidomide and bortezomib in patients
relapsed after an allograft has been reported in several
studies [37,38]. Furthermore, profound “immunomodulary
effects” after allografting have already been observed. Higher
response rates to salvage therapies, which translated into
better OS, were reported in patients who had received a prior
allograft rather than an autograft in a comparative study [19].
However, new drugs, such as lenalidomide, should be
incorporated in clinical protocols as consolidation and/or
maintenance with a degree of caution given that recently
reported toxicity may be partly related to doses and treat-
ment schedule [39]. Other strategies may include pre-
emptive donor lymphocyte infusions with/without new
drugs [40,41].
Our study did not allow for a comprehensive analysis
of the impact of cytogenetic abnormalities because most
patients were diagnosed when standard cytogenetic or
FISH analyses had not yet become part of the diagnostic
work-up. Research showed that abnormalities such as
del(17p) are associated with shorter response duration
and poor prognosis even after treatment with “new drugs”
[42]. A retrospective analysis by the Société Francaise de
Greffe de Moelle et de Thérapie Cellulaire showed that
patients who carry these high-risk abnormalities may
most beneﬁt from an allograft [43]. With the introduction
of new drugs, allografting has gradually become a less
attractive treatment option. However, prospective studies
may evaluate its current role in selected high-risk and/or
refractory patients earlier in the course of the disease to
limit the risk of cumulative toxicity and the potential
emergence of plasma cell clones resistant to graft-versus-
myeloma effects.
Before the introduction of reduced-intensity and/or
nonmyeloablative conditioning, TRMwas unacceptably high,
up to 60% [44-46]. The wider use of reduced-intensity
conditioning has recently shifted the burden of myeloma
eradication and control from the pretransplantation inten-
sive chemoradiotherapy of the conditioning to graft-versus-
myeloma effects. A retrospective EBMT analysis showed that
reduced-intensity conditioningwas associatedwith less TRM
but higher risk of relapse as compared with myeloablative
conditioning [47]. It may be worth revisiting the role of more
intense conditioning. Comorbidity scores, speciﬁcally
designed for hematopoietic cell transplantations, may help
to choose the intensity of the conditioning and to better
select patients [48,49]. Moreover, high-resolution HLA
typing at an allele level is currently more readily available for
both class I and II MHC antigens in donor registries, and
a fully matched HLA donor should be highly preferable.
Table 4
Univariate and Multivariate Analyses (Cox Models) for EFS
Variable Univariate Analyses Multivariate Analyses
HR 95% CI P HR 95% CI P
Durie-Salmon stage (III vs. I-II) 1.31 .93-1.85 .126
Previous therapy lines (>2 vs.  2) 1.28 .94-1.75 .115 .97 .63-1.50 .895
Disease status at transplant .009 .605
PR vs. CR 1.83 1.08-3.11 .025 1.06 .49-2.30 .879
SD-PD vs. CR 2.28 1.34-3.89 .002 .85 .39-1.84 .674
Recipientedonor HLA matched alleles .095 .886
9/10 vs. 10/10 1.31 .92-1.86 .132 .92 .57-1.48 .731
8/10 vs. 10/10 1.53 1.00-2.35 .050 1.08 .56-2.09 .820
Recipientedonor gender combinations .901
f.f. vs. m.f. 1.16 .67-1.99 .598
m.m. vs. m.f. 1.16 .76-1.78 .503
f.m. vs. m.f. 1.18 .74-1.89 .492
New drugs before allograft (yes vs. no) .99 .70-1.41 .961
Source (PBSC vs.BM) .75 .53-1.06 .098 1.02 .54-1.92 .951
Conditioning .052 .025
R vs. M 1.34 .90-2.00 .145 1.96 1.16-3.33 .001
NM vs. M .84 .56-1.27 .405 1.22 .71-2.08 .478
ATG (yes vs. no) 1.08 .79-1.47 .645
Acute GVHD* 1.12 .74-1.68 .593 1.15 .62-2.15 .658
Chronic GVHD* .54 .31-.97 .040 .82 .45-1.50 .516
Chronic GVHD* .047
Limited vs. no GVHD .51 .29-.89 .017
Extensive vs. no GVHD .55 .28-1.08 .082
Best response posttransplantation* <.001 <.001
PR vs. CR 1.98 1.07-3.67 .029 2.13 1.34-3.41 .002
SD-PD vs. CR 4.85 2.29-1.29 <.001 4.25 2.41-7.50 <.001
Year of transplant .459
2003-2005 vs. 2000-2002 1.14 .69-1.89 .599
2006-2009 vs. 2000-2002 .92 .57-1.47 .722
f. indicates female; m., male; BM, bone marrow; R, reduced intensity; M, myeloablative; NM, nonmyeloablative; vs., versus.
* Treated as a time-dependent variable.
R. Passera et al. / Biol Blood Marrow Transplant 19 (2013) 940e948946Unlike other reports, however, we did not ﬁnd any correla-
tion between donor gender and clinical outcomes [50].
In summary, younger medically ﬁt patients, with
high-risk cytogenetics, may be offered more intense condi-
tionings to combine profound cytoreduction and potential
graft-versus-myeloma effects, whereas older unﬁt patients,
because of comorbidities, may best beneﬁt from debulking
therapies followed by a reduced-intensity and/or non-
myeloablative allograft to avoid unacceptably high TRM. This
treatment planmay be explored in future prospective control
studies through the IBMDR.
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